MedTrace Logo

Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women

NCT07735897 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1483

Last updated 2026-07-31

No results posted yet for this study

Summary

This study evaluates the long-term effects of adding 2 years of ovarian function suppression (OFS) to tamoxifen therapy in young premenopausal women with hormone receptor-positive breast cancer after chemotherapy. The study will assess recurrence, breast cancer-specific survival, and overall survival beyond 10 years to determine the long-term benefits of OFS treatment.

Conditions

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • MedicalExcellence

    lead OTHER

Principal Investigators

  • heejeong Kim, MD · Asan Medical Center

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2034-03-01
Completion
2034-05-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07735897 on ClinicalTrials.gov